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Abstract
Historically, mortality rates for liver failure have been high, regardless of the 
type. With new advancements in liver transplantation (LTx), 1-year survival rates 
have improved up to 95% in most recent estimates. While some patients may live 
past the critical period, the majority of patients do not survive the interval period 
for awaiting LTx or liver regeneration. The function of the liver to detoxify and 
correct several biochemical parameters has been achieved to some extent through 
artificial liver support technology, although constant innovations are still being 
developed for the most optimal liver support device. The complex function of the 
liver makes it challenging since it does not only detoxify toxic by-products but also 
participates in numerous other synthetic and metabolic functions of the body. 
Liver support systems are divided into an artificial liver assist device (ALD) and 
a bioartificial liver assist device (BLD). ALDs include molecular adsorbent recir-
culating system (MARS), Prometheus, single-pass albumin dialysis, and selective 
plasma filtration therapy. These devices work as a blood purification system of the 
liver. On the other hand, BLD has hepatic cell lines incorporated in its equipment, 
which aims to function as a complex biological liver system providing support to 
its biochemical processes. Several clinical and randomized trials have conflicting 
results on the survival of the patients with acute liver failure (ALF), and the ideal 
liver support system still seems a far-off goal.
Keywords: liver failure, liver assist devices, bioartificial liver assist device,  
artificial liver assist device
1. Background
In the last decade, liver-related deaths have been steadily increasing. In 2016, 
it was responsible for more than one million deaths across the world [1]. ALF is 
defined as a rapid onset deterioration of liver function with coagulopathy and 
onset of encephalopathy of a previously healthy individual. It can be further 
classified into hyper-acute, acute, and sub-acute according to the O’Grady system 
of classification. The clinical manifestation includes jaundice, encephalopathy, and 
hematemesis or melena; however, unlike chronic liver disease, ascites and portal 
hypertension are rarely seen. The common etiologies include acute viral hepatitis, 
drug-induced liver injury, and ischemic hepatocellular injury. High mortality rates 
are associated with ALF [2]. Supportive therapy options are limited in the interim 
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between the development of ALF until liver function improves/or the patient 
undergoes liver LTx. Due to limited organ availability for patients waiting for LTx, 
and the rapid deterioration of a patient with ALF, the mortality rate approaches 
approximately 50% [3, 4].
Numerous studies are ongoing in an attempt to delay or prevent the need for LTx 
in patients with ALF. Artificial hepatic assist devices, auxiliary liver transplanta-
tion, a liver dialysis system, and xenotransplantation are the most sought-after 
therapeutic options. Several liver assist devices (LAD) have been manufactured 
since the 1990s on the pathophysiological basis of albumin dialysis, the best-known 
being the following: the molecular adsorbent recirculating system (MARS), single-
pass albumin dialysis system (SPAD), and the fractionated plasma separation and 
adsorption system –FPSA (Prometheus). These systems remove the albumin-bound 
toxins that accumulate in liver failure. Older techniques previously were not able 
to remove these toxins and maybe the reason for the ineffectiveness of tradition-
ally designed devices. The knowledge gained from these provided a platform for a 
better understanding of newer LADs, to perform the liver’s functions more effec-
tively. LADs facilitate the removal of water-soluble substances, such as ammonia, 
urea, and other smaller proteins, such as some cytokines, by standard dialysis [3]. 
Removal of these cytokines and other identifiable inducers of hepatic encephalopa-
thy (HE), such as amino acids (e.g., tryptophan or glutamine), reduces the grade 
of HE and consequently reduces complications of liver failure [5]. Furthermore, 
they function to remove conjugated or unconjugated bilirubin, protoporphyrin, bile 
acids, glycoside derivatives, phenols, short- and medium-chain fatty acids, such as 
octanoate, or heterocyclic organic compounds. In one study, removal of plasmatic 
nitric oxide (NO) and some pro-inflammatory and anti-inflammatory cytokines 
lead to the improvement of clinical conditions of HE, renal and respiratory func-
tion, and hemodynamic derangement and subsequent sequential organ failure [6].
LAD designed to treat patients with ALF are classified into two main categories: 
non-cell-based systems, including plasmapheresis, plasma exchange, albumin 
dialysis, and charcoal-based hemadsorption, and systems that incorporate hepatic 
tissue (bioartificial liver support systems) [7, 8].
In the last decade, a significant shift in the development of these devices has 
emerged. The utility and efficacy of these new LADs are currently being evaluated 
in the clinical setting.
1.1 Types of liver support systems
Liver support systems are divided broadly into two categories: biological and 
mechanical. Artificial or mechanical liver support consists of artificial and bio-
artificial systems. Two artificial systems, the MARS, and the SPAD, clear selected 
toxins; however, they provide no synthetic support, nor do they improve survival in 
a randomized clinical trial (RCT) [9].
Biological systems combine the functional potential of hepatocyte incorporation 
with that of hemodialysis, enabling non-invasive, continuous treatment for patients 
with ALF. Regardless of their safety and cost-effectiveness, they do not improve 
portal hypertension or portosystemic shunting [9].
1.2 Artificial liver support devices
1.2.1 Molecular adsorbent recirculating system (MARS)
MARS was developed in 1990 and is the most widely published and clinically 
used artificial liver support system (Figure 1). The method is based on two basic 
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principles: protein-binding affinity and solute movement, which acts along the 
concentration gradient [10]. The combination of conventional dialysis against 
an albumin dialysate is utilized, followed by a traditional procedure of dialysis 
to remove the toxins from the dialysate [11]. It is composed of a blood circuit, an 
albumin circuit (containing 60 ml of 20% human albumin, charcoal column, and 
an anion exchange column with cholestyramine), and a traditional “renal” dialysate 
circuit as shown in Figures 2–3. Blood is passed through an albumin-incorporated 
high-flux dialysis membrane into which hydrophobic water-soluble and protein-
bound toxins are released. The removal of toxins eventually takes place through the 
diffusion process, which depends on the free toxin level (mainly affected by the 
molar ratio of a toxin to albumin). The albumin dialysate is then recycled and is able 
to accept further toxins until both columns are saturated, eliminating the need for 
continuous infusion of albumin.
MARS can also eliminate cytokines and modify the inflammatory response 
involved in liver failure. Cytokines have been implicated in the development of 
HE, systemic inflammatory response syndrome (SIRS), vasodilation, and multiple 
organ failure. These proteins mediate hepatic inflammation, cholestasis, and 
liver cell necrosis and apoptosis [12]. Furthermore, studies have shown signifi-
cant removal of some pro-inflammatory cytokines when using MARS, such as 
TNF-α, interleukin-6, and interleukin-1 β, and anti-inflammatory cytokines, 
such as interleukin-10 [13]. However, other studies were unable to demonstrate 
an effective change in the plasma cytokine concentration in patients with liver 
failure, possibly due to the high rate of its production [14]. Donati et al. showed 
269 patients treated with MARS with no effect on cytokine plasma levels but a 
significant rise in hepatic growth factor concentration (enhances liver regenera-
tion) [15]. In another study, Dominik et al. demonstrated some beneficial results 
in an in vitro study, where MARS improved the elimination of some cytokines 
with more extensive pore membranes, which could be attributed to optimizing the 
cytokine plasma profile of patients [16]. Ultimately, the precise roles of differ-
ent cytokines in the pathophysiology of liver failure and the influence of MARS 
on cytokine profiles are yet to be understood and could be an exciting topic for 
further research.
Figure 1. 
Molecular adsorption recirculation system (MARS). Adapted from https://www.slideshare.net/tyfngnc/
salon-a-17-kasim-2011-1410-1430-ender-egedik.
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Interestingly, some authors have been exploring other active substances that can 
also be eliminated by MARS. In one study, Gay et al. demonstrated that in patients 
with cholestasis and pruritus, the proteins dialyzed and then absorbed in the anion-
exchange resin cartridge of MARS showed elimination of some biologically relevant 
proteins, such as secreted Ly6/uPAR-related protein-1 (SLURP1) or defensin 
human neutrophil peptide-1 (HNP-1), which are involved in the inflammatory and 
defensive processes [17].
When using MARS, particular attention should be given to the monitoring of 
some critical drugs during treatment, such as fluoroquinolones and meropenem, 
with dose adjustments done to ensure therapeutic levels.
Figure 2. 
Cartridges in MARS. Adapted from Tawada Healthcare | Gambro Equipment Supplier.
Figure 3. 
Schema of the operating principle in MARS. Adapted from Karla et al. Extracorporeal liver support devices 
for Listed patients. Liver Transplantation 22839–8482016 AASLD.
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Anticoagulation during MARS is also essential to consider issue since there is a 
delicate hemostatic balance that needs to be maintained in patients with liver failure 
who are at high risk of bleeding. The most used drug in practice is unfractionated 
heparin, but there are some concerns regarding hemorrhagic risk and heparin-
induced thrombocytopenia. Also, some studies have explored the use of continuous 
extracorporeal systems without anticoagulation and have found a comparable cir-
cuit lifespan [18]. The anticoagulant-free approach may also be a reasonable option 
in patients with a high risk of bleeding. Citrate has been shown to be safe with 
longer treatment time, preventing filter loss [19]. However, its regular use needs 
to be validated in an RCT. Unfractionated heparin is the anticoagulant of choice in 
most clinical trials, but some studies have also used local citrate anticoagulation, 
with no reported adverse effects [19].
Technical issues have also been raised about the stability of the binding proper-
ties of albumin after passing the adsorber columns or about the clinical relevance 
of some stabilizers (such as octanoate) used in commercially available albumin 
preparations [20]. However, there are no definitive conclusions, and these issues 
should be addressed in further studies.
Regarding clinical outcomes, mostly retrospective studies were published in 
the first years following the debut of MARS. Most of them showed usefulness 
in the treatment of HE, and some even demonstrated improvement in terms of 
hemodynamic parameters. The few RCT evaluating survival showed conflicting 
results [21, 22]. These trials included studied a few patients diagnosed with acute-
on-chronic liver failure. In a recent study of 27 patients who received MARS therapy 
for severe ALF, survival rate was 60% (n = 3/5) for patients with severe liver trauma, 
78% (n = 7/9) for patients who used MARS as a bridge to transplantation, and 67% 
(n = 6/9) when MARS was used as definitive therapy for toxic ingestion or idiopathic 
liver failure [23].
Lastly, MARS has led us to discover its benefit in drug-induced liver injury 
(DILI) cases [24]. Statistically speaking, about 50% of cases of ALF are likely due 
to DILI in the United States [25, 26]. The standard of medical therapy (SMT) is 
the withdrawal of offending drugs and supportive therapy [27]. A review of the 
literature indicates several cases of reports of DILI involving several drugs. The 
most common offending drugs are acetaminophen, nonsteroidal anti-inflammatory 
drugs, isoniazid, and amoxicillin/clavulanate [28]. However, there are several 
potential hepatotoxic agents of DILI leading to ALF [29–31].
1.2.2 Fractionated plasma separation and adsorption—FPSA (Prometheus)
Falkenhagen et al. described the first method of FPSA for the use of ALF 
[32]. The device is shown in Figure 4. Prometheus uses endogenous albumin to 
pass through the circuit using the AlbuFow filter (molecular cut-off of 250 kDa) 
(Figure 5). Albumin is reactivated and returned to circulation using a neutral 
resin adsorber (Prometh 01) and an anion-exchange column (Prometh 02). 
Subsequently, the patient’s blood then passes through a second circuit, where it is 
treated by conventional high-flux hemodialysis, eventually returning blood to the 
patient.
During the first decade of its use in the market, Prometheus showed better 
efficacy than MARS for both in vitro and in vivo trials in removing ammonia, 
bilirubin, or bile acids [33]. In 2009, Grodzicki et al. also showed a significant 
decline in serum ammonia, bilirubin, aspartate aminotransferase, alanine ami-
notransferase, urea, and creatinine with the use of Prometheus in patients with 
ALF [34]. Furthermore, Rifai et al. showed a decline in almost all 26 of the amino 
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acids measured in nine patients with liver failure with a single treatment session. 
Prometheus is also hypothesized to improve the complications of HE due to the 
removal of amino acids such as glutamine, phenylamine, tyrosine, and tryptophan, 
which all have been noted to be contributing factors to HE, and thus, may help 
to improve outcomes in patients with liver failure [35]. In an experimental study 
of ALF by Ryska et al., Prometheus showed a significant decrease in intracranial 
pressure (ICP) in pigs to that of the control group (24 mmHg versus 29.8 mmHg, 
respectively, p < 0.05) suggesting that its use in the removal of amino acids in that 
contribute to the development of HE [36].
Rosen et al. also showed a significant reduction in most cytokines and tumor 
necrosis factor with Prometheus, potentially highlighting its possible role in the 
treatment of liver failure [37, 38]. Despite showing this drastic decrease, no other 
Figure 4. 
Fractionated plasma separation and adsorption—FPSA (Prometheus). Adapted from http://dialize.lv. Slokas 
iela 84-1A, Rīga, LV-1007.
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improvement was seen aside from improvement of HE clinically. There was also note 
of a significant surge in hepatocyte growth factor (HGF) concentration, which stimu-
lates liver regeneration. Similar to MARS, there was no significant impact shown in 
the cytokine profile, and further research needs to be done in this area of study.
In terms of survival and clinical outcomes, Laleman et al. published an article 
comparing SMT with MARS and Prometheus in a patient with acute-on-chronic 
liver failure and it showed MARS to have better outcomes in terms of hemodynamic 
parameters (mean arterial pressure, stroke volume, systemic resistance) [38]. 
Dethloff et al. also revealed similar findings in the improvement of mean arterial 
pressure in patients with decompensated liver cirrhosis with the MARS session as 
opposed to Prometheus and conventional hemodialysis [39]. Both of the modalities 
(MARS and Prometheus) decrease cytokines and inflammatory markers; however, 
there is no exact explanation for these hemodynamic changes.
Kribben et al. in 2012 conducted a multicentric RCT (HELIOS study) compar-
ing Prometheus versus SMT in 145 patients with acute-on-chronic liver failure; the 
primary endpoints are survival at 28 days and 90 days [19]. The overall survival of 
the Prometheus group compared to the SMT group was 47% versus 38% but did not 
show any statistical significance.
In the subgroup analysis of patients with advanced liver disease (MELD >30), 
there was a significantly higher 90-day survival probability (48% versus 9%, 
p < 0.05) for the Prometheus group compared to SMT. This highlights a possible 
benefit of Prometheus for treating advance liver disease patients, although the small 
sample size of the group limits its generalizability to the population.
Over time, other studies derived differing conclusions in regard to its clinical 
benefit. Sentürk el al. compared the biochemical and clinical parameters for FPSA 
in patients with ALF and acute-on-chronic liver failure, and showed a significant 
improvement in the biochemical parameters in HE, although survival rates were not 
addressed in this study [40]. Similarly, Komardina et al. also showed hemodynamic 
and biochemical improvements with Prometheus in patients with ALF, but without 
any difference in survival outcomes [41].
Figure 5. 
Schema of Prometheus. Adapted from Karla et al. Extracorporeal Liver support devices for listed patients. 
Liver Transplantation 22839–8482016 AASLD.
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1.2.3 Single-pass albumin dialysis (SPAD)
Single-pass albumin dialysis (SPAD) is a simple technique of blood purifica-
tion without the sophisticated blood purification line and can be implemented 
in any intensive care unit applying a standard CRRT. The blood is passed across 
and dialyzed through a high-flux hollow-fiber hemodiafilter containing albumin-
impregnated dialysate, as shown in Figure 6. Dialysate is discarded once it passes 
through the dialyzer, which uses high amounts of exogenous albumin, effectively 
making it significantly more expensive than MARS, which recycles endogenous 
albumin [17].
Sauer et al. studied SPAD and MARS, and both were shown to be better than 
continuous venovenous hemodiafiltration (CVVHD) in removing water-soluble 
and protein-bound compounds (bilirubin and bile acids) using 4.4% albumin 
dialysate solution [42]. Kortgen et al. also confirmed these results by comparing 
the detoxification capacity in patients with liver failure [43]. Both had a significant 
reduction in serum bilirubin levels, although MARS had a better result in lowering 
the urea and creatinine level. The limitation of the study was its retrospective and 
non-randomized nature, and fewer patients were in the SPAD group than there 
were in the MARS group.
Several studies were conducted to assess the efficacy of dialysate solution con-
centration for optimal results while carrying out SPAD. Churchwell et al. demon-
strated that the highest effectiveness was achieved with 5% albumin dialysate and a 
larger polysulfone dialyzer (surface area 1.5 m2). Subsequently, Schmuck et al. and 
Benyoub et al. demonstrated an optimal detoxification efficacy for albumin-bound 
substances such as bilirubin and bile acids with a 3–3.2% albumin concentration and 
a dialysate flow rate of 1000 mL/h using SPAD with a conventional CVVHD and a 
high-flux polysulfone hemodiafilter [44].
There were only a few case reports published for SPAD immediately after its 
introduction, and currently, there are no published studies that emphasize on 
demonstrating the clinical benefits of SPAD versus SMT in ALF. Two uncontrolled 
retrospective studies in pediatric and adult patients with ALF treated with SPAD 
as rescue therapy were previously done but neither had conclusive evidence show-
ing their clinical effectiveness, although both noted its ease of use and absence of 
complications [45].
The most recent RCT done by Sponholz et al. comparing SPAD versus MARS 
demonstrated a similar decline in the total plasma bilirubin levels, without signifi-
cant differences between these two LAD modalities [46]. However, the reduction 
in the total bile acids and γ-glutamyl transferase levels in the patient treated with 
Figure 6. 
Schema of SPAD. Adapted from Karla et al. Extracorporeal liver support devices for Listed patients. Liver 
Transplantation 22839–8482016.
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SPAD was non-significant. Furthermore, the creatinine and urea levels were not 
significantly reduced with SPAD compared to those of MARS. The aforementioned 
results were differing in other studies, where there was a note of metabolic abnor-
malities with SPAD, such as a rise in lactate levels or a decline in calcium levels. This 
could be attributed possibly to the preferential use of citrate anticoagulation with a 
low dialysis flow rate. In these studies, The MARS and SPAD demonstrated a slight 
improvement in the HE and hemodynamic status.
Regardless of the ease of administration of SPAD as compared to MARS, the 
standard albumin dialysate concentration, dialysate flow rate, and standard of care 
are not yet fully established.
1.3 Other devices
New systems are currently being developed, building on previous knowledge 
of LADs.
Marangoni et al. described a high-efficiency MARS by incorporating a double 
adsorption system (double columns containing charcoal and another pair with 
ion-exchange resin) into the albumin circuit [47]. The detoxification potential of 
modified MARS was compared with that of the “classical” MARS in four patients 
with liver failure and demonstrated that “improved” MARS was potentially more 
efficient in reducing bilirubin and bile acids.
Another system currently being studied conducted by Akcan Arikan et al. pre-
sented the usefulness of high-flux CRRT for hyperammonemia, therapeutic plasma 
exchange for coagulopathy, and MARS for HE. This retrospective observational 
study showed that 15 pediatric patients with ALF or acute-on-chronic liver failure 
showed improvement in hepatic encephalopathy with these modalities [48].
More recently, Al-Chalabi et al. and Huber et al. published an animal model of 
ALF, and patients with liver failure respectively. A modified device called advanced 
organ support (ADVOS) was first presented in 2013, which included a dialysate 
circuit containing standard dialysate with a 2–4% albumin concentration, an 
extracorporeal blood circuit, and a third and last circuit where the albumin dialy-
sate was separated into two parts. Each part would undergo a PH and temperature 
change before reaching the cation and anion filters, resulting in dialysates that have 
albumin that is free of toxins [49, 50]. This is accomplished by adding and removing 
acid or base. The dialysates containing toxin-free albumin then join with each other 
to reach the expected pH before entering the hemodialyzer again. Huber et al. also 
showed the same result with ADVOS in reducing bilirubin levels. However, no other 
studies were further published recently.
Some other modification techniques such as plasma diafiltration, plasma 
exchange, or therapeutic apheresis using a bilirubin adsorbent column were also 
published in literature anecdotally [51–53].
1.4 Bioartificial liver support devices
In the last 10 years, significant developments were made with bioartificial liver 
support devices. These systems are designed to be able to mimic the synthetic and 
regulatory functions of the liver, in conjunction with the use of LADs to detoxify 
the patient’s plasma. Tumor cell lines, developing expandable progenitor cell 
populations, or primary human cells can be used, although the most widely used are 
xenogeneic derivations of primary porcine cells, due to their availability, although 
there is a risk of infection (i.e., porcine retrovirus infection) and metabolic incom-
patibility (i.e., graft-versus-host disease, drug-induced thrombocytopenia, comple-
ment clotting cascade activation).
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1.4.1 Extracorporeal liver assist device (ELAD)
Extracorporeal liver assist device (ELAD) consists of hepatoblastoma C3A cell 
line, derived from human hepatoblastoma cell line HepG2. Cells are localized in the 
extra capillary space of a modified dialysis cartridge with a membrane cut-off of 
70 kDa to prevent immunoglobulins, blood cells, and C3A tumorigenic cells from 
crossing [54].
This modality was first developed by Sussman et al. and was assessed in King’s 
College Hospital in London in a pilot-controlled study done by Ellis et al. for 
patients with ALF who were judged to have >50% survival still and in those who 
were already indicated for LTx. Twenty-four patients were randomly divided into 
two groups of ELAD hemoperfusion or control. Overall survival in the ELAD 
hemoperfusion group was 7 of 9 (78%), and survival for the controls was unexpect-
edly high, 6 of 8 (75%). Due to the small sample size, the study failed to prove an 
improvement in the survival rate of patients with ALF [55].
Working off of the initial ELAD, Millis et al. studied a modified version of 
ELAD to determine the safety profile of the device for patients with fulminant 
hepatic failure [56]. All patients successfully had an LTx, with four out of the five 
patients surviving the 30-day survival endpoint of the study, with no noted biome-
chanical problems or hemodynamic instability. The authors concluded that ELAD is 
safe and can be conducted on a larger scale in multi-center RCTs.
1.4.2 Bioartificial liver—HepatAssist
Bioartificial liver (BAL) works on the concept of combining hepatocyte bioreac-
tor with a column filled with cultured hepatocytes to mimic liver function. Arbios 
first described BAL devices, which the Food and Drug Administration approved 
for Phase I, II, and III clinical trials. In HepatAssist, the patient’s blood is initially 
separated into plasma and cellular components. The plasma is then passed through 
a high-flow plasma circulation loop and then successively through a charcoal filter, 
oxygenator, heater, and a hollow fiber bioreactor containing 7 billion cryopreserved 
hepatocytes. The resulting processed plasma then combines again with the cellular 
components and sent back to the patient’s blood [3].
In the study of Watanabe et al., 31 patients were enrolled in a Phase I study, with 
the goal of developing a BAL for patients with severe liver failure until they can 
be transplanted or recover spontaneously [57]. Sixteen out of 18 (89%) patients 
in group 1 were successfully bridged to LTx. The same goes for group 2 patients 
(n = 3); all were bridged successfully to transplantation, while group 3 (n = 10) 
had two who were supported to recovery and LTx. The remaining eight patients in 
group 3 expired since they were not candidates for LTx.
Other Phase II and III clinical trials from multiple centers across US and 
European centers involving 171 patients (86 controls and 85 treated) were con-
ducted to study the efficacy of this device in patients with ALF. Inclusion criteria 
were patients with Stage III or IV HE or with primary non-function of the trans-
planted liver. The groups were randomized, receiving standard of care and daily 
treatment with HepatAssist for 7 hours. Results for this trial were inconclusive and 
failed to show an improvement in 30-day survival rates, although a good safety 
profile was noted.
Subgroup analysis indicated that the HepatAssist session might provide an 
improvement in survival rate in patients, especially with drug and chemical 
toxicity-induced liver failure [58]. Recently, according to Arbios Systems, Inc., there 
is a study underway to assess a version of HepatAssist with 15–20 billion porcine 
hepatocytes to be studied in Phase III clinical trials [3].
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1.4.3 Modular extracorporeal liver support (MELS)
Modular extracorporeal liver support (MELS) was developed in Germany and 
is based on tailoring the extracorporeal therapy units to the clinical need of the 
patient. In a Phase I study using porcine hepatocytes-based BALs, eight patients 
with ALF showed that it might be beneficial as a bridge to a liver transplant. The 
limitations are its high cost and complicated design, which may become an obstacle 
for its wide availability [3].
1.4.4 Academic Medical Center (Amsterdam)-BAL
In contrary to other BAL support devices, this modality is incorporated with 
capillaries for oxygenation and viability [54]. Preliminary studies are promising; 
however, more extensive trials are needed to validate its efficacy.
When comparing MELS to AMC-BAL, both have shown comparable efficiency. 
Although in one study, it was demonstrated that ammonia and lidocaine removal 
was significantly higher in AMC-BAL as compared to MELS. However, LDH was 
observed to be considerably lower in MELS.
Several other liver support devices have been developed across the world such as 
the Hybrid-BAL (Nanjing, China), TECA-Hybrid Artificial Liver Support System 
(Beijing, China), the Bioartificial Hepatic Support (Udine, Italy), and the Radial 
Flow Bioreactor (Ferrara, Italy), although further research is required to assess their 
efficacy and safety [59].
2. Conclusion
ALF, despite being treated medically, is linked with high mortality. Due to longer 
wait time for liver donors in patients who require LTx, many patients with ALF will, 
unfortunately, die while waiting for a transplant. Therefore, a liver support system is 
necessary as a “bridge” to final treatment or until the liver regenerates upon removal of 
the inciting cause. Over the last 20 years, many artificial liver support systems with the 
potential to emerge as an ideal device with advances have been introduced. At present, 
whether BALs can reduce mortality in the ALF population remains controversial.
BALs incorporating human primary hepatocytes are the most suitable cells but are 
limited by low availability due to a shortage of donor organs. The development of an 
implantable liver system where hepatocytes can be cultured on substrates to mimic 
the lobular structure of the liver is promising. However, mimicking the vascular and 
biliary connections of the liver and recreating all of the necessary metabolic and 
biochemical functions of the liver will be challenging. As technology is continually 
evolving, only time will tell the future of these innovative liver assist devices and their 
possible impact on human culture and health and well-being of affected individuals.
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